ABOS
Acumen Pharmaceuticals, Inc. (NASDAQ)
Healthcare — Biotechnology
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Price History
Fundamentals
| Market Cap | $189.24M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.74 |
| EPS (TTM) | $-1.85 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $7.40 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 68.2 |
| Beta | 0.35 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | - |
Performance Analysis
BULLISHABOS shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 01, 2026 11:46 UTC
Back to Screener Export Report